![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/04/2892897/0/en/Pharvaris-Highlights-Properties-of-Deucrictibant-in-Data-Presentations-at-Recent-Congresses.html
https://www.globenewswire.com/news-release/2024/04/04/2857613/0/en/Pharvaris-to-Present-Deucrictibant-Clinical-Data-at-the-CIIC-Spring-2024-Conference.html
https://www.globenewswire.com/news-release/2024/03/18/2847642/0/en/Pharvaris-Announces-Phase-3-Clinical-Study-Design-for-Recently-Initiated-RAPIDe-3-Study-and-Presents-Quality-of-Life-Improvement-and-Caregiver-Behavior-Data-at-Two-Recent-HAE-Congr.html
https://www.globenewswire.com//news-release/2024/02/22/2833499/0/en/Positive-Results-from-CHAPTER-1-Phase-2-Study-of-Deucrictibant-for-the-Prophylactic-Treatment-of-HAE-Attacks-to-be-Presented-at-AAAAI-2024-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/01/22/2812879/0/en/Pharvaris-Announces-FDA-Lifting-of-the-Clinical-Hold-of-Deucrictibant-for-the-Prophylactic-Treatment-of-HAE-Attacks.html
https://www.globenewswire.com/news-release/2023/12/06/2791612/0/en/Pharvaris-Announces-Positive-Top-line-Phase-2-Data-from-the-CHAPTER-1-Study-of-Deucrictibant-for-the-Prophylactic-Treatment-of-HAE-Attacks.html
https://www.globenewswire.com/news-release/2023/06/26/2694273/0/en/Pharvaris-Announces-FDA-Removal-of-Clinical-Hold-of-Deucrictibant-for-the-On-Demand-Treatment-of-HAE.html